American pharmaceutical giant Johnson & Johnson (JNJ) is boosting its U.S. investments by 25% to more than $55 billion over ...

Johnson & Johnson has laid out plans to raise U.S. investments by 25% to more than $55 billion over the next four years, as a ...

Johnson & Johnson (JNJ) announced its plans to invest over $55 billion over the next four years in the U.S. to strengthen its ...

Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American ...

The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease ...

Pfizer's attractive dividend yield and low P/E ratio make it appealing. Learn why PFE stock's valuation risks may be higher ...

Johnson & Johnson (NYSE:JNJ) on Friday announced plans to boost its U.S. investments to more than $55B over the next four ...

Johnson & Johnson (NYSE:JNJ) experienced an 11% share price increase over the last quarter, coinciding with pivotal ...

JNJ stock hits Golden Cross, signaling potential long-term upside. Latest breakthrough in lung cancer treatment could provide additional catalyst.

J&J will now pick up almost the full tab for the phase 3 trial, and, in return, Nanobiotix will see the potential milestone ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy ...

Data evaluating safety and early signals of efficacy including updated local PFS from the completed dose escalation part of a Phase 1 study of re-irradiation with JNJ-1900 (NBTXR3) for patients ...